HomeCompareAGRPY vs ABBV

AGRPY vs ABBV: Dividend Comparison 2026

AGRPY yields 7.27% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AGRPY wins by $56451.21M in total portfolio value
10 years
AGRPY
AGRPY
● Live price
7.27%
Share price
$27.37
Annual div
$1.99
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56451.31M
Annual income
$54,998,166,854.86
Full AGRPY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — AGRPY vs ABBV

📍 AGRPY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAGRPYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AGRPY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AGRPY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AGRPY
Annual income on $10K today (after 15% tax)
$618.01/yr
After 10yr DRIP, annual income (after tax)
$46,748,441,826.63/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, AGRPY beats the other by $46,748,420,770.63/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AGRPY + ABBV for your $10,000?

AGRPY: 50%ABBV: 50%
100% ABBV50/50100% AGRPY
Portfolio after 10yr
$28225.71M
Annual income
$27,499,095,813.31/yr
Blended yield
97.43%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

AGRPY
No analyst data
Altman Z
0.4
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AGRPY buys
0
ABBV buys
0
No recent congressional trades found for AGRPY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAGRPYABBV
Forward yield7.27%3.06%
Annual dividend / share$1.99$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$56451.31M$102.3K
Annual income after 10y$54,998,166,854.86$24,771.77
Total dividends collected$56351.66M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AGRPY vs ABBV ($10,000, DRIP)

YearAGRPY PortfolioAGRPY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$12,154$1,454.15$11,550$430.00+$604.00AGRPY
2$16,308$3,303.54$13,472$627.96+$2.8KAGRPY
3$25,735$8,285.41$15,906$926.08+$9.8KAGRPY
4$51,976$24,438.76$19,071$1,382.55+$32.9KAGRPY
5$147,870$92,255.79$23,302$2,095.81+$124.6KAGRPY
6$648,811$490,590.20$29,150$3,237.93+$619.7KAGRPY
7$4,717,725$4,023,497.33$37,536$5,121.41+$4.68MAGRPY
8$59,732,488$54,684,522.14$50,079$8,338.38+$59.68MAGRPY
9$1,358,075,698$1,294,161,935.83$69,753$14,065.80+$1358.01MAGRPY
10$56,451,307,852$54,998,166,854.86$102,337$24,771.77+$56451.21MAGRPY

AGRPY vs ABBV: Complete Analysis 2026

AGRPYStock

Absa Group Limited, together with its subsidiaries, provides various financial products and services in South Africa and internationally. The company operates through Retail and Business Banking; Corporate and Investment Banking; and Head Office, Treasury and Other Operations. It provides retail, business, corporate, investment banking, insurance, financial, and wealth management products and services. The company offers retail and business banking products and services to individual, enterprise, and commercial customers, including residential property-related finance solutions; vehicle and asset finance products and services; credit cards; personal loans; relationship banking; short-term insurance products; transactional banking, savings, and investment products and services; and rewards program and services. It also provides commercial property finance and term loans. In addition, the company offers investment banking services; private equity and infrastructure investments; corporate banking products and services; and wealth management services. Further, it provides life insurance products covering death, disability and retrenchment, funeral, and life wrapped investment products; investments, such as asset management, multi-management, unit trusts, and investment products; treasury services; and wealth and financial advisory services. Additionally, the company offers market services; trade and working capital solutions; and cash management, payment, and liquidity products and solutions. It also offers broker-dealer trading in debt and equity securities; and solicitation, syndication, selling, and arranging of equity and debt products, as well as financial, leasing, and management services. The company was formerly known as Barclays Africa Group Limited and changed its name to Absa Group Limited in May 2018. Absa Group Limited was incorporated in 1986 and is based in Johannesburg, South Africa.

Full AGRPY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this AGRPY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AGRPY vs SCHDAGRPY vs JEPIAGRPY vs OAGRPY vs KOAGRPY vs MAINAGRPY vs JNJAGRPY vs MRKAGRPY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.